The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The 2023 San Antonio Breast Cancer Symposium (SABCS), held Dec. 5-9 at the city’s Henry B. Gonzalez Convention Center, had a record-setting attendance with 10,874 registered attendees from 102 countries.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Virginia Kaklamani, MD
Professor of medicine, Department of Hematology/Oncology, UT Health San Antonio; Leader of the Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center
Srivani Ravoori, PhD
Director of science communications, American Association for Cancer Research
Carlos L. Arteaga, MD
Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

Byline
Virginia Kaklamani, MD
Professor of medicine, Department of Hematology/Oncology, UT Health San Antonio; Leader of the Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center
Srivani Ravoori, PhD
Director of science communications, American Association for Cancer Research
Carlos L. Arteaga, MD
Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account